Table 1.
IR+ (% uninjured) | MI+ (% uninjured) | |
---|---|---|
Myogenesis | ||
IGF-I | 71 | 63 |
IGF-II | 43 | 64 |
IGFBP-2 | 65 | 65 |
IGFBP-3 | 107 | 122 |
IGFBP-5 | 109 | 126 |
IGFBP-6 | 109 | 110 |
bFGF | 106 | 97 |
HGF R | 0 | 19 |
Angiogenesis | ||
VEGF | 132 | 113 |
VEGF R1 | 103 | 138 |
VEGF R2 | 0 | 0 |
VEGF R3 | 0 | 0 |
VEGF-D | 0 | 0 |
ECM remodelling | ||
MMP-2 | 65 | 153 |
MMP-3 | 87 | 52 |
TIMP-1 | 93 | 85 |
TIMP-2 | 96 | 73 |
Pro-MMP-9 | 44 | 48 |
Chemokines | ||
Fractalkine | 111 | 90 |
GCSF | 95 | 91 |
GM-CSF | 91 | 97 |
KC (IL8) | 129 | 113 |
MCP1 | 75 | 85 |
MCP-5 | 72 | 79 |
MIP-1_ | 136 | 104 |
MIP-1_ | 196 | 135 |
MIP-2 | 146 | 119 |
MIP-3 _ | 153 | 113 |
MIP-3_ | 132 | 118 |
RANTES | 119 | 141 |
Inflammation | ||
IL-1 b | 117 | 94 |
IL-6 | 89 | 69 |
TNF_ | 107 | 92 |
sTNF RI | 146 | 94 |
sTNF RII | 135 | 102 |